MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
This article was originally published in The Gray Sheet
Executive Summary
Preliminary results of Boston Scientific's MADIT-CRT study show a significant benefit for cardiac resynchronization therapy implants over conventional defibrillators for patients with mild heart failure; the data could support expanded labeling and increased market adoption for the premium-priced devices, industry watchers say
You may also be interested in...
Medtronic-Sponsored Economic Analysis Supports CRT Devices As Cost-Effective
New analysis from the Medtronic-sponsored REVERSE trial shows that patients with mild heart failure receiving CRT therapy had an ICER (incremental cost effectiveness ratio) of $8,840 per QALY, compared to those not receiving CRT.
ESC Guidelines: CRT Gets Nod For Mild Symptoms, But Not Asymptomatic HF
New European 1guidelines provide strong support for extending cardiac resychronization therapy to a broader set of heart failure patients, but not quite the same population as an FDA panel recently recommended in the U.S
ESC Guidelines: CRT Gets Nod For Mild Symptoms, But Not Asymptomatic HF
New European 1guidelines provide strong support for extending cardiac resychronization therapy to a broader set of heart failure patients, but not quite the same population as an FDA panel recently recommended in the U.S